Merck & Company: Product KL-798
Merck has been approached by a small biotech research firm with the proposal that Merck buy the rights to a new drug that promises to treat obesity and lower cholesterol. The drug is in the middle of phase I of the FDA approval process. Pat Harlow, the chief licensing officer, has been leading Merck's investigation team. A meeting is scheduled for tomorrow at which Merck's response to the offer will be drafted.
Collection: Darden University of Virginia (USA)
Ref: DARDEN-QA-0582-E
Format: PDF
Number of pages: 4
Publication Date: Jul 9, 2001
Language: English, Spanish
Review date: Jun 14, 2016
What material is included in this case:
Description
Merck has been approached by a small biotech research firm with the proposal that Merck buy the rights to a new drug that promises to treat obesity and lower cholesterol. The drug is in the middle of phase I of the FDA approval process. Pat Harlow, the chief licensing officer, has been leading Merck's investigation team. A meeting is scheduled for tomorrow at which Merck's response to the offer will be drafted.
Read more
Industry Setting: Pharmaceuticals/Biotechnology/Health Care
Leave your rating
"Merck & Company: Product KL-798"
Register for free with IESE Publishing and enjoy all the advantages
What type of account do you want to create?
Choose account type
Professors
Academic Institutions
Companies
Individuals